A new addition to the drugs exploiting the incretin system, the glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 dual agonist tirzepatide is among the furthest developed multi-agonists for diabetes care and has so far displayed promising nephroprotective effects. The gene discussed is GCG; the disease is diabetes mellitus.